| scholarly article | Q13442814 |
| P2093 | author name string | Wolfram Sterry | |
| Bruce Freundlich | |||
| Olivier Brocq | |||
| Bruce Kirkham | |||
| Jean-Paul Ortonne | |||
| Charles T Molta | |||
| Ronald D Pedersen | |||
| Deborah Robertson | |||
| Joanne Estojak | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| psoriatic arthritis | Q511097 | ||
| P304 | page(s) | c147 | |
| P577 | publication date | 2010-02-02 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. | |
| P478 | volume | 340 |
| Q44639027 | A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis |
| Q90664422 | A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis |
| Q38840271 | A Review of Psoriasis, Therapies, and Suicide. |
| Q38084325 | A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q38858335 | A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis |
| Q37868389 | Advances in the treatment of moderate-to-severe plaque psoriasis |
| Q38386298 | An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis |
| Q36479450 | Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis |
| Q37741879 | Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice |
| Q64921248 | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. |
| Q46085062 | Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q39837952 | Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial |
| Q92308398 | Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison |
| Q36033361 | Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment |
| Q38013239 | Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan |
| Q55452701 | Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. |
| Q30251926 | Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q38099408 | Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. |
| Q33747197 | Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world |
| Q51329120 | Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. |
| Q41449533 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis |
| Q38198080 | Efficacy and safety of etanercept in chronic immune-mediated disease |
| Q38785383 | Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe |
| Q38153077 | Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials |
| Q37743492 | Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis |
| Q38137277 | Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points |
| Q90465560 | Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis |
| Q34103030 | Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment |
| Q47329414 | Enthesitis: from pathophysiology to treatment |
| Q35020358 | Etanercept biosimilars |
| Q38027577 | Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence |
| Q46536030 | Etanercept use for psoriasis in Taiwan: a case series study. |
| Q38230740 | Etanercept: a review of its use in autoimmune inflammatory diseases |
| Q38838470 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. |
| Q92737255 | Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q39373505 | New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease |
| Q48238696 | Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. |
| Q44849386 | Patient preferences for psoriasis treatments: impact of treatment experience |
| Q44773623 | Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept |
| Q41888146 | Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis |
| Q38667430 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis |
| Q38630548 | Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. |
| Q48170767 | Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. |
| Q90470107 | Psoriatic arthritis |
| Q38542095 | Psoriatic arthritis: latest treatments and their place in therapy |
| Q37758453 | Psoriatic arthritis: pharmacotherapy update |
| Q91597152 | Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience |
| Q38161956 | Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update |
| Q48559584 | Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens |
| Q37520856 | Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. |
| Q47260366 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. |
| Q26764867 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies |
| Q45917463 | Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. |
| Q30235002 | The Changing Face of Clinical Trials in Psoriatic Arthritis |
| Q51359715 | The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psori |
| Q57481895 | The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA |
| Q55631301 | The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis. |
| Q34973745 | The cost of biologics for psoriasis is increasing |
| Q45221388 | The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). |
| Q38098466 | Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents |
| Q38644270 | Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials. |
| Q38690324 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
| Q39003610 | Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. |
| Q27012134 | Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature |
| Q92737085 | What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials |
| Q42769613 | What's new in dermatological treatments? |
| Q84324567 | [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions] |
| Q52927228 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q53760739 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q85054900 | [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy] |
| Q84441824 | [Update on psoriasis at the Dermatology Day conference, Paris 2010] |
Search more.